HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MALT lymphoma of the small bowel with protein-losing enteropathy.

Abstract
Mucosa-associated lymphoid tissue (MALT) lymphoma usually arises from chronic inflammation. We herein report a case of small intestinal MALT lymphoma with protein-losing enteropathy (PLE). A 73-year-old woman presented with lower leg edema and severe hypoalbuminemia. She had a medical history of pylorus-preserving pancreaticoduodenectomy with Billroth II reconstruction. Oral and anal route double-balloon enteroscopies revealed irregular nodular mucosal lesions with erosion extending from the jejunum to terminal ileum. Histopathological evaluation of the biopsied mucosa showed proliferation of small-to-medium-sized lambda light chain-restricted B cells. Plasmacytic differentiation and lymphoepithelial lesions were present, leading to the diagnosis of MALT lymphoma. Tc-99m albumin scintigraphy indicated tracer exudation in the small bowel, suggesting the presence of PLE. Combination immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen improved both MALT lymphoma and PLE, whereas rituximab monotherapy was not successful. This case is considered to be common type of MALT lymphoma at an uncommon site and is distinct from immunoproliferative small intestinal disease (IPSID). To our knowledge, this is the first case of non-IPSID-type small intestinal MALT lymphoma complicated by PLE. Gastrointestinal reconstruction may be responsible for underlying chronic inflammation via small intestinal bacterial overgrowth.
AuthorsAyato Tsukamoto, Fumihiko Nakamura, Yasuhito Nannya, Yuka Kobayashi, Junji Shibahara, Motoshi Ichikawa, Masashi Fukayama, Kazuhiko Koike, Mineo Kurokawa
JournalInternational journal of hematology (Int J Hematol) Vol. 99 Issue 2 Pg. 198-201 (Feb 2014) ISSN: 1865-3774 [Electronic] Japan
PMID24395281 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Aged
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cyclophosphamide (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Female
  • Humans
  • Ileal Neoplasms (drug therapy, pathology, physiopathology)
  • Ileum (drug effects, pathology, physiopathology)
  • Intestinal Mucosa (drug effects, pathology, physiopathology)
  • Jejunal Neoplasms (drug therapy, pathology, physiopathology)
  • Jejunum (drug effects, pathology, physiopathology)
  • Lymphoma, B-Cell, Marginal Zone (drug therapy, pathology, physiopathology)
  • Prednisone (therapeutic use)
  • Protein-Losing Enteropathies (etiology, prevention & control)
  • Rituximab
  • Treatment Outcome
  • Vincristine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: